Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• Analysts give Kalaris Therapeutics an average recommendation of "Moderate Buy" from seven analysts, with a consensus 12‑month price target of $14.00 and Morgan Stanley initiating coverage at an "overweight" rating and $14 target.
• Institutional investors own 66.05% of the company, with several large new stakes reported recently (e.g., RTW Investments ~$10.97M and Paradigm Biocapital Advisors ~$5.91M), signaling notable institutional interest.
• Shares opened at about $6.11 (12‑month range $2.14–$11.88) and the company reported quarterly EPS of −$0.44, beating estimates, while analysts project a full‑year EPS of about −2.18.

Shares of Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seven analysts that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $14.00.

KLRS has been the topic of a number of research analyst reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Kalaris Therapeutics in a research report on Monday, December 29th. Wall Street Zen raised shares of Kalaris Therapeutics from a "sell" rating to a "hold" rating in a research report on Sunday, March 15th. Finally, Morgan Stanley initiated coverage on shares of Kalaris Therapeutics in a research report on Thursday, April 16th. They set an "overweight" rating and a $14.00 price target on the stock.

Institutional Trading of Kalaris Therapeutics

A number of institutional investors have recently bought and sold shares of the company. RTW Investments LP bought a new stake in Kalaris Therapeutics during the fourth quarter valued at $10,972,000. Paradigm Biocapital Advisors LP bought a new stake in Kalaris Therapeutics during the fourth quarter valued at $5,908,000. Siren L.L.C. boosted its position in Kalaris Therapeutics by 36.9% during the fourth quarter. Siren L.L.C. now owns 435,798 shares of the company's stock valued at $3,678,000 after acquiring an additional 117,534 shares during the last quarter. Alyeska Investment Group L.P. bought a new stake in Kalaris Therapeutics during the fourth quarter valued at $3,402,000. Finally, Ikarian Capital LLC acquired a new position in shares of Kalaris Therapeutics during the fourth quarter valued at about $3,038,000. Institutional investors own 66.05% of the company's stock.

Kalaris Therapeutics Price Performance

Shares of Kalaris Therapeutics stock opened at $6.11 on Monday. Kalaris Therapeutics has a twelve month low of $2.14 and a twelve month high of $11.88. The stock has a market cap of $140.10 million, a price-to-earnings ratio of -1.45 and a beta of 0.18. The company's fifty day moving average is $7.75 and its 200 day moving average is $7.48.

Kalaris Therapeutics (NASDAQ:KLRS - Get Free Report) last issued its quarterly earnings data on Tuesday, March 17th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.12. As a group, equities analysts anticipate that Kalaris Therapeutics will post -2.18 earnings per share for the current fiscal year.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.